MCID: ORT004
MIFTS: 68

Orthostatic Intolerance

Categories: Genetic diseases, Neuronal diseases, Rare diseases, Mental diseases, Cardiovascular diseases

Aliases & Classifications for Orthostatic Intolerance

MalaCards integrated aliases for Orthostatic Intolerance:

Name: Orthostatic Intolerance 57 76 75 37 29 13 6
Mitral Valve Prolapse 12 76 37 29 55 6 43 44 15 63
Neurocirculatory Asthenia 57 12 44 15 73
Mitral Valve Prolapse Syndrome 57 73
Irritable Heart 57 73
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 59
Cardiovascular Malfunction Arising from Mental Factors 12
Postural Tachycardia Syndrome Due to Net Deficiency 59
Orthostatic Intolerance Due to Net Deficiency 59
Mitral Valve Prolapse, Familial, X-Linked 73
Myxomatous Mitral Valve Prolapse 12
Systolic Click-Murmur Syndrome 12
Intolerance, Orthostatic 40
Cardiovascular Neurosis 12
Mitral Leaflet Syndrome 12
Floppy Mitral Valve 12
Da Costa's Syndrome 12
Krishaber's Disease 12
Barlow's Syndrome 12
Soldiers Heart 57
Oi 75

Characteristics:

Orphanet epidemiological data:

59
orthostatic intolerance due to net deficiency
Inheritance: Autosomal dominant;

HPO:

32
orthostatic intolerance:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare neurological diseases


Summaries for Orthostatic Intolerance

MedlinePlus : 43 Mitral valve prolapse (MVP) occurs when one of your heart's valves doesn't work properly. The flaps of the valve are "floppy" and don't close tightly. Most people who have the condition are born with it. It also tends to run in families. Most of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can cause Palpitations (feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast) Shortness of breath Cough Fatigue, dizziness, or anxiety Migraine headaches Chest discomfort Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications. If you need treatment for MVP, medicines can help relieve symptoms or prevent complications. Very few people will need surgery to repair or replace the mitral valve. MVP puts you at risk for infective endocarditis, a kind of heart infection. To prevent it, doctors used to prescribe antibiotics before dental work or certain surgeries. Now, only people at high risk of endocarditis need the antibiotics. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Orthostatic Intolerance, also known as mitral valve prolapse, is related to mitral valve prolapse 1 and ehlers-danlos syndrome, hypermobility type, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Orthostatic Intolerance is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and NFAT and Cardiac Hypertrophy. The drugs Midodrine and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes, and related phenotypes are orthostatic tachycardia and cardiovascular system

UniProtKB/Swiss-Prot : 75 Orthostatic intolerance: Syndrome characterized by lightheadedness, fatigue, altered mentation and syncope. It is associated with postural tachycardia. Plasma norepinephrine concentration is abnormally high.

Disease Ontology : 12 A mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole.

PubMed Health : 63 About mitral valve prolapse: Mitral (MI-tral) valve prolapse (MVP) is a condition in which the heart's mitral valve doesn't work well. The flaps of the valve are "floppy" and don't close tightly. These flaps normally help seal or open the valve.Much of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can lead to palpitations, shortness of breath, chest pain, and other symptoms. (Palpitations are feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast.)

Wikipedia : 76 Mitral valve prolapse (MVP; a.k.a. floppy mitral valve syndrome, systolic click murmur syndrome or... more...

Description from OMIM: 604715

Related Diseases for Orthostatic Intolerance

Diseases in the Orthostatic Intolerance family:

Chronic Orthostatic Intolerance

Diseases related to Orthostatic Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 mitral valve prolapse 1 35.4 DCHS1 MMVP1
2 ehlers-danlos syndrome, hypermobility type 30.6 FBN1 PLOD1
3 autonomic dysfunction 30.4 DBH ECE1
4 mitral valve prolapse 2 12.7
5 mitral valve prolapse 3 12.6
6 chronic orthostatic intolerance 12.4
7 postural orthostatic tachycardia syndrome 12.0
8 brittle bone disorder 12.0
9 osteogenesis imperfecta, type v 11.9
10 osteogenesis imperfecta, type iv 11.9
11 osteogenesis imperfecta, type ii 11.9
12 osteogenesis imperfecta, type viii 11.8
13 osteogenesis imperfecta, type iii 11.7
14 osteogenesis imperfecta, type xiii 11.7
15 osteogenesis imperfecta, type xiv 11.7
16 osteogenesis imperfecta, type xv 11.7
17 osteogenesis imperfecta, type i 11.7
18 osteogenesis imperfecta, type vii 11.7
19 osteogenesis imperfecta, type xi 11.7
20 mitral valve prolapse, familial, x-linked 11.7
21 osteogenesis imperfecta, type x 11.6
22 osteogenesis imperfecta, type vi 11.6
23 osteogenesis imperfecta, type xii 11.6
24 dentinogenesis imperfecta 11.3
25 osteogenesis imperfecta, type ix 11.1
26 platelet membrane fluidity 10.9 NOS2 NOS3
27 resting heart rate, variation in 10.8 ADRA2B ADRB1 ADRB2
28 ocular hypotension 10.8 ADRB1 ADRB2
29 persistent fetal circulation syndrome 10.8 EDN1 NOS3 POMC
30 hepatopulmonary syndrome 10.7 EDN1 NOS2 NOS3
31 coronary artery vasospasm 10.7 EDN1 MGAM NOS3
32 scleredema adultorum 10.7 FBN1 POMC
33 perinephritis 10.7 ADRB2 EDN1 MGAM
34 raynaud phenomenon 10.7 ADRA2C AGTR1 EDN1
35 impotence 10.7 EDN1 NOS2 NOS3
36 meningococcal infection 10.7 ADRB1 ADRB2 AGTR1
37 renovascular hypertension 10.6 AGTR1 EDN1 NOS3
38 ischemic optic neuropathy 10.6 AGTR1 EDN1 NOS3
39 collagen disease 10.6 EDN1 FBN1 PLOD1
40 nonarteritic anterior ischemic optic neuropathy 10.6 AGTR1 EDN1 NOS3
41 renal hypertension 10.6 AGTR1 DBH EDN1
42 portal hypertension 10.5 AGTR1 EDN1 NOS3
43 arteries, anomalies of 10.5 AGTR1 EDN1 NOS3
44 mitral valve disease 10.5 AGTR1 FBN1 NOS3
45 acute mountain sickness 10.5 ADRB2 AGTR1 EDN1 NOS3
46 congestive heart failure 10.5 ADRB1 ADRB2 AGTR1 EDN1
47 syncope 10.5
48 chronic rhinitis 10.5 ECE1 EDN1
49 renal artery disease 10.4 AGTR1 NOS3
50 cerebritis 10.3

Graphical network of the top 20 diseases related to Orthostatic Intolerance:



Diseases related to Orthostatic Intolerance

Symptoms & Phenotypes for Orthostatic Intolerance

Clinical features from OMIM:

604715

Human phenotypes related to Orthostatic Intolerance:

32
# Description HPO Frequency HPO Source Accession
1 orthostatic tachycardia 32 HP:0012173

UMLS symptoms related to Orthostatic Intolerance:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Orthostatic Intolerance:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 ECE1 EDN1 FBN1 NOS2 NOS3 PLOD1
2 behavior/neurological MP:0005386 10.31 ADRB2 AGTR1 DBH FBN1 NOS2 NOS3
3 homeostasis/metabolism MP:0005376 10.31 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
4 growth/size/body region MP:0005378 10.28 ACHE ADRA2B ADRB1 ADRB2 AGTR1 DBH
5 mortality/aging MP:0010768 10.27 AGTR1 DBH DCHS1 ECE1 EDN1 FBN1
6 adipose tissue MP:0005375 10.16 POMC ACHE ADRB1 ADRB2 AGTR1 DBH
7 endocrine/exocrine gland MP:0005379 10.11 ADRB2 DBH ECE1 EDN1 FBN1 NOS2
8 nervous system MP:0003631 10.1 EDN1 FBN1 NOS2 NOS3 POMC SLC6A2
9 muscle MP:0005369 10.02 ACHE ADRA2B ADRB1 ADRB2 ECE1 EDN1
10 no phenotypic analysis MP:0003012 9.7 ACHE ADRB1 ADRB2 DCHS1 FBN1 PLOD1
11 renal/urinary system MP:0005367 9.56 ADRA2B AGTR1 DCHS1 EDN1 FBN1 NOS2
12 skeleton MP:0005390 9.32 ADRB1 ADRB2 DBH DCHS1 ECE1 EDN1

Drugs & Therapeutics for Orthostatic Intolerance

PubMedHealth treatment related to Orthostatic Intolerance: 63

Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications.Even people who do have symptoms may not need treatment. The presence of symptoms doesn't always mean that the backflow of blood through the valve is significant.People who have MVP and troublesome mitral valve backflow usually need treatment. MVP is treated with medicines, surgery, or both.The goals of treating MVP include:Preventing infective endocarditis (IE), arrhythmias, and other complicationsRelieving symptomsCorrecting the underlying mitral valve problem, if necessary

Drugs for Orthostatic Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
2
Metoprolol Approved, Investigational Phase 4,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
3
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 525-66-6 4946
4
Bisoprolol Approved Phase 4 66722-44-9 2405
5
Fludrocortisone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 127-31-1 31378
6
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23651-95-8 443940
7 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
19 Sympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Vasodilator Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anticonvulsants Phase 4,Phase 2,Phase 1
22 Bromides Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Cholinergic Agents Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 101-26-8
26 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
28 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 83-43-2 6741
31
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-24-8 5755
32
Dopamine Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
33
Levodopa Approved Phase 3,Phase 1,Early Phase 1 59-92-7 6047
34
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
35
Carbidopa Approved Phase 2, Phase 3,Phase 3,Phase 1 28860-95-9 34359 38101
36
Methyldopa Approved Phase 3,Phase 1 555-30-6 38853
37
Losartan Approved Phase 3,Early Phase 1 114798-26-4 3961
38
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
39
Metoclopramide Approved, Investigational Phase 3,Phase 1 364-62-5 4168
40
Atenolol Approved Phase 3,Phase 1,Phase 2 29122-68-7 2249
41 tannic acid Approved, Nutraceutical Phase 2, Phase 3
42 Antiemetics Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
43 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1,Not Applicable
44 Gastrointestinal Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 glucocorticoids Phase 2, Phase 3,Not Applicable
46 Hormone Antagonists Phase 2, Phase 3,Not Applicable
47 Hormones Phase 2, Phase 3,Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Not Applicable
49 Methylprednisolone acetate Phase 2, Phase 3,Not Applicable
50 Methylprednisolone Hemisuccinate Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
3 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
4 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
5 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
6 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
7 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
8 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
9 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
10 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
11 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
12 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
13 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
14 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
15 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
16 TQL-block for Laparoscopic Hemicolectomy Not yet recruiting NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
17 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Not yet recruiting NCT03229174 Phase 4 Droxidopa;Placebo
18 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
19 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3 Methylprednisolone;Isotonic Sodium Chloride
20 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3 Midodrine;Placebo
21 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
22 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
23 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
24 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
25 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
26 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
27 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Recruiting NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
28 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Recruiting NCT03182725 Phase 3 Ivabradine;Placebo
29 Treatment of Post-SCI Hypotension Recruiting NCT02919917 Phase 2, Phase 3 Midodrine Hydrochloride;Midodrine Hydrochloride
30 Peripheral Dopamine in Postural Tachycardia Syndrome Active, not recruiting NCT00685919 Phase 2, Phase 3 Carbidopa;Placebo
31 Treatment of Orthostatic Hypotension Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
32 A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
33 Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients Terminated NCT01612078 Phase 3 Droxidopa;Placebo
34 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
35 Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome Withdrawn NCT01361087 Phase 3
36 The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome Unknown status NCT01761825 Phase 2 ivabradine
37 Cardiovascular Effects of Selective I(f)-Channel Blockade Unknown status NCT00865917 Phase 2 beta-blocker (Metoprolol);I(f)-blocker (ivabradine);Placebo
38 Fipamezole in Neurogenic Orthostatic Hypotension Unknown status NCT00758849 Phase 2 Placebo;Fipamezole
39 Safety and Efficacy Study of a New Device for Making Neochordae in Mitral Valve Repair Unknown status NCT01811537 Phase 1, Phase 2
40 Sex Hormones and Orthostatic Tolerance Completed NCT01153581 Phase 2 Ganirelix acetate;17β-Oestradiol;Progesterone
41 Non-Pharmacologic Therapy for Neurocardiogenic Syncope Completed NCT00096902 Phase 2
42 Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance Completed NCT00093860 Phase 2 Propranolol
43 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed NCT00977665 Phase 2 rasagiline mesylate;placebo
44 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI Completed NCT02307526 Phase 2 Pyridostigmine Bromide
45 Intravenous Norepinephrine for Orthostatic Hypotension Completed NCT01285908 Phase 1, Phase 2 Intravenous Norepinephrine Infusion
46 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Completed NCT00004268 Phase 2 midodrine
47 Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD) Completed NCT01971008 Phase 2
48 Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury Completed NCT01874782 Phase 2
49 Safety and Efficacy of L-NAME and Midodrine to Increase MAP Completed NCT00835224 Phase 2 L-NAME;Midodrine;Placebo
50 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride Completed NCT00426842 Phase 2 Midodrine Hydrochloride

Search NIH Clinical Center for Orthostatic Intolerance

Cochrane evidence based reviews: neurocirculatory asthenia

Genetic Tests for Orthostatic Intolerance

Genetic tests related to Orthostatic Intolerance:

# Genetic test Affiliating Genes
1 Orthostatic Intolerance 29 SLC6A2
2 Mitral Valve Prolapse 29

Anatomical Context for Orthostatic Intolerance

MalaCards organs/tissues related to Orthostatic Intolerance:

41
Heart, Brain, Testes, Lung, Spinal Cord, Bone, Endothelial

Publications for Orthostatic Intolerance

Articles related to Orthostatic Intolerance:

(show top 50) (show all 964)
# Title Authors Year
1
Unusual combination of mitral valve prolapse, bicuspid aortic valve, and ventricular septal defect restricted by the tricuspid septal leaflet. ( 29339711 )
2018
2
Intravenous saline administration in patients with severe acquired brain injury and orthostatic intolerance for tilt-table mobilization. ( 29190150 )
2018
3
Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection. ( 29650052 )
2018
4
Orthostatic tachycardia with different onset time in patients with orthostatic intolerance. ( 29801880 )
2018
5
Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. ( 29969498 )
2018
6
Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment. ( 29696346 )
2018
7
The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). ( 29588088 )
2018
8
Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope. ( 29519640 )
2018
9
Pediatric Disorders of Orthostatic Intolerance. ( 29222399 )
2018
10
Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. ( 29519641 )
2018
11
Changes in the augmentation index and postoperative orthostatic intolerance in orthopedic surgery: a prospective cohort study. ( 29790120 )
2018
12
Prefrontal hemodynamic changes measured using near-infrared spectroscopy during the Valsalva maneuver in patients with orthostatic intolerance. ( 29392157 )
2018
13
Association of blood pressure variability with orthostatic intolerance symptoms. ( 28591231 )
2017
14
Mitral valve prolapse and Marfan syndrome. ( 28580713 )
2017
15
Orthostatic Intolerance and Postural Orthostatic Tachycardia Syndrome in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type: Neurovegetative Dysregulation or Autonomic Failure? ( 28286774 )
2017
16
Dominant Transmission Observed in Adolescents and Families With Orthostatic Intolerance. ( 27773421 )
2017
17
Syndromes of orthostatic intolerance and syncope in young adults. ( 28674628 )
2017
18
Early Orthostatic Hypotension and Orthostatic Intolerance-More Than an Observation or Annoyance. ( 28738118 )
2017
19
Patients with Orthostatic Intolerance: Relationship to Autonomic Function Tests results and Reproducibility of Symptoms on Tilt. ( 28720881 )
2017
20
The effects of body weight status on orthostatic intolerance and predisposition to noncardiac syncope. ( 28112481 )
2017
21
Novel insights into symptomatology of moyamoya disease in pediatric patients: survey of symptoms suggestive of orthostatic intolerance. ( 28862519 )
2017
22
Orthostatic Intolerance in Older Persons: Etiology and Countermeasures. ( 29163185 )
2017
23
Common origin of all three coronary arteries from the right sinus of Valsalva - first case study accompanied by mitral valve prolapse and vein anomaly, second case study followed by successful percutaneous coronary intervention of right coronary artery stenosis. ( 28515755 )
2017
24
Cardiovascular and Cutaneous Responses to the Combination of Alcohol and Soft Drinks: The Way to Orthostatic Intolerance? ( 29176950 )
2017
25
The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. ( 28738696 )
2017
26
Truncal ataxia or disequilibrium is an unrecognised cause of orthostatic intolerance in patients with myalgic encephalomyelitis. ( 28613452 )
2017
27
Monitoring of cerebral oximetry during head-up tilt test in adults with history of syncope and orthostatic intolerance. ( 29036615 )
2017
28
A Rare Case of Mitral Valve Prolapse in Endomyocardial Fibrosis. ( 27549547 )
2016
29
A rare case of right sided pulmonary artery agenesis associated with congenital mitral valve prolapse. ( 27481086 )
2016
30
Mechanisms of orthostatic intolerance during heat stress. ( 26723547 )
2016
31
Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome. ( 27729043 )
2016
32
Sudden cardiac arrest and coexisting mitral valve prolapse: a case report and literature review. ( 27249812 )
2016
33
Distinct neurohumoral biomarker profiles in children with hemodynamically defined orthostatic intolerance may predict treatment options. ( 26608337 )
2016
34
Orthostatic intolerance and fatigue in the hypermobility type of Ehlers-Danlos Syndrome. ( 27094596 )
2016
35
Incidental left anterior descending coronary artery to pulmonary artery fistula in myxomatous mitral valve prolapse. ( 27751341 )
2016
36
Antroduodenal Manometry is Abnormal in Children Presenting with Orthostatic Intolerance and Gastrointestinal Symptoms. ( 26859090 )
2016
37
Dizziness and Orthostatic Intolerance In Pediatric Headache Patients. ( 27017026 )
2016
38
Postoperative orthostatic intolerance: a common perioperative problem with few available solutions. ( 27638295 )
2016
39
Orthostatic hypertension: An underestimated cause of orthostatic intolerance. ( 26806722 )
2016
40
Reduced Systolic Volume: Main Pathophysiological Mechanism in Patients with Orthostatic Intolerance? ( 27849259 )
2016
41
Orthostatic intolerance and autonomic dysfunction following bariatric surgery: A retrospective study and review of the literature. ( 27292926 )
2016
42
Detailed Relationship Between the Pattern of Blood Pressure Change During the Valsalva Maneuver and the Degree of Orthostatic Hypotension During the Head-Up Tilt Test in Patients With Orthostatic Intolerance: A Retrospective Case-Control Study. ( 27175668 )
2016
43
Adolescent Chronic Fatigue and Orthostatic Intolerance: Relationships Between Parental Attributes and Child Functioning. ( 27421749 )
2016
44
Evolution of Mitral Valve Prolapse: Insights From the Framingham Heart Study. ( 27006478 )
2016
45
Hiatal hernia, mitral valve prolapse and defecatory disorders: An underlying rectal prolapse? ( 26925980 )
2016
46
Genetic association analyses highlight biological pathways underlying mitral valve prolapse. ( 26301497 )
2015
47
New recessive truncating mutation in LTBP3 in a family with oligodontia, short stature, and mitral valve prolapse. ( 25899461 )
2015
48
Cortical Morphology in Patients with Orthostatic Intolerance. ( 25895544 )
2015
49
Postexercise orthostatic intolerance: influence of exercise intensity. ( 26040636 )
2015
50
Autonomic activity and biomarker behavior in supine position and after passive postural stress in different orthostatic intolerance syndromes. ( 26320094 )
2015

Variations for Orthostatic Intolerance

UniProtKB/Swiss-Prot genetic disease variations for Orthostatic Intolerance:

75
# Symbol AA change Variation ID SNP ID
1 SLC6A2 p.Ala457Pro VAR_010022 rs121918126

ClinVar genetic disease variations for Orthostatic Intolerance:

6
(show top 50) (show all 141)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh37 Chromosome 16, 55731917: 55731917
2 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh38 Chromosome 16, 55698005: 55698005
3 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
4 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022
5 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh38 Chromosome 2, 202559777: 202559777
6 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh37 Chromosome 2, 203424500: 203424500
7 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh38 Chromosome 16, 55656746: 55656746
8 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh38 Chromosome 16, 55656513: 55656513
9 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh37 Chromosome 16, 55690425: 55690425
10 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh38 Chromosome 16, 55656715: 55656715
11 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh37 Chromosome 16, 55690627: 55690627
12 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh38 Chromosome 16, 55656742: 55656742
13 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh37 Chromosome 16, 55690654: 55690654
14 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh37 Chromosome 16, 55690658: 55690658
15 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh37 Chromosome 16, 55703462: 55703462
16 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh38 Chromosome 16, 55669550: 55669550
17 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh37 Chromosome 16, 55725912: 55725912
18 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh38 Chromosome 16, 55692000: 55692000
19 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh37 Chromosome 16, 55725975: 55725975
20 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh38 Chromosome 16, 55692063: 55692063
21 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh37 Chromosome 16, 55732392: 55732392
22 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh38 Chromosome 16, 55698480: 55698480
23 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh37 Chromosome 16, 55732456: 55732456
24 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh38 Chromosome 16, 55698544: 55698544
25 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh37 Chromosome 16, 55736672: 55736673
26 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh38 Chromosome 16, 55702717: 55702717
27 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh37 Chromosome 16, 55736629: 55736629
28 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs886052135 GRCh38 Chromosome 16, 55702742: 55702743
29 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs886052135 GRCh37 Chromosome 16, 55736654: 55736655
30 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh38 Chromosome 16, 55702760: 55702761
31 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh38 Chromosome 16, 55702762: 55702762
32 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh37 Chromosome 16, 55736674: 55736674
33 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh38 Chromosome 16, 55702763: 55702763
34 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh37 Chromosome 16, 55736675: 55736675
35 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh38 Chromosome 16, 55702952: 55702952
36 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh37 Chromosome 16, 55736864: 55736864
37 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs886052140 GRCh38 Chromosome 16, 55703265: 55703267
38 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs886052140 GRCh37 Chromosome 16, 55737177: 55737179
39 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh38 Chromosome 16, 55703363: 55703363
40 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh37 Chromosome 16, 55737275: 55737275
41 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh38 Chromosome 16, 55703521: 55703521
42 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh37 Chromosome 16, 55737433: 55737433
43 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh38 Chromosome 16, 55671926: 55671926
44 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh37 Chromosome 16, 55705838: 55705838
45 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh37 Chromosome 16, 55725894: 55725894
46 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh38 Chromosome 16, 55691982: 55691982
47 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh37 Chromosome 16, 55731946: 55731946
48 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh38 Chromosome 16, 55698034: 55698034
49 SLC6A2 NM_001043.3(SLC6A2): c.1489+9G> A single nucleotide variant Uncertain significance rs760893401 GRCh38 Chromosome 16, 55698577: 55698577
50 SLC6A2 NM_001043.3(SLC6A2): c.1489+9G> A single nucleotide variant Uncertain significance rs760893401 GRCh37 Chromosome 16, 55732489: 55732489

Expression for Orthostatic Intolerance

Search GEO for disease gene expression data for Orthostatic Intolerance.

Pathways for Orthostatic Intolerance

Pathways related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2
Show member pathways
12.72 ADRA2A ADRA2B ADRB1 ADRB2 EDN1
3
Show member pathways
12.51 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
4
Show member pathways
12.33 ADRA2A ADRA2B ADRA2C ADRB2 POMC
5
Show member pathways
12.07 ADRB1 ADRB2 AGTR1 NOS2 NOS3
6
Show member pathways
12 ADRA2A ADRA2B ADRA2C NOS2 NOS3
7 11.75 EDN1 NOS2 NOS3
8 11.74 AGTR1 EDN1 NOS3
9
Show member pathways
11.73 ADRA2A ADRA2B ADRA2C
10
Show member pathways
11.72 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
11 11.69 ECE1 NOS3 POMC
12 11.5 ADRB1 ADRB2 AGTR1
13 11.42 ADRA2A ADRB1 ADRB2
14
Show member pathways
11.29 ACHE DBH SLC6A2
15 11.02 ACHE ADRB1 ECE1 EDN1
16 10.79 ADRB1 ECE1 EDN1 NOS3
17 10.65 NOS2 NOS3
18 10.53 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 DBH
19 10.43 NOS2 NOS3

GO Terms for Orthostatic Intolerance

Cellular components related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
2 integral component of plasma membrane GO:0005887 9.7 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
3 Weibel-Palade body GO:0033093 8.62 ECE1 EDN1

Biological processes related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.91 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 EDN1
2 positive regulation of MAPK cascade GO:0043410 9.86 ADRA2A ADRA2B ADRA2C ADRB2
3 platelet activation GO:0030168 9.82 ADRA2A ADRA2B ADRA2C
4 kidney development GO:0001822 9.81 AGTR1 DCHS1 FBN1
5 glucose homeostasis GO:0042593 9.8 ADRA2A DBH POMC
6 regulation of blood pressure GO:0008217 9.77 EDN1 NOS3 POMC
7 regulation of insulin secretion GO:0050796 9.75 ADRA2A ADRA2C NOS2
8 activation of protein kinase B activity GO:0032148 9.72 ADRA2A ADRA2B ADRA2C
9 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.72 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
10 peptide hormone processing GO:0016486 9.66 ECE1 POMC
11 response to pain GO:0048265 9.65 DBH SLC6A2
12 regulation of sodium ion transport GO:0002028 9.65 ADRB2 NOS3
13 negative regulation of norepinephrine secretion GO:0010700 9.65 ADRA2A ADRA2B ADRA2C
14 regulation of blood vessel size GO:0050880 9.64 EDN1 NOS3
15 nitric oxide mediated signal transduction GO:0007263 9.64 NOS2 NOS3
16 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.63 ECE1 EDN1 NOS3
17 regulation of blood vessel diameter GO:0097746 9.62 ADRB2 AGTR1
18 negative regulation of calcium ion transport GO:0051926 9.62 ADRA2A NOS3
19 nitric oxide biosynthetic process GO:0006809 9.61 NOS2 NOS3
20 negative regulation of multicellular organism growth GO:0040015 9.61 ADRB1 ADRB2
21 negative regulation of epinephrine secretion GO:0032811 9.61 ADRA2A ADRA2B ADRA2C
22 positive regulation of guanylate cyclase activity GO:0031284 9.6 NOS2 NOS3
23 diet induced thermogenesis GO:0002024 9.58 ADRB1 ADRB2
24 epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway GO:0035625 9.58 ADRA2A ADRA2B ADRA2C
25 arginine catabolic process GO:0006527 9.57 NOS2 NOS3
26 regulation of smooth muscle contraction GO:0006940 9.56 ADRA2A ADRA2B ADRA2C ADRB2
27 heat generation GO:0031649 9.54 ADRB1 ADRB2
28 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.52 ADRB1 ADRB2
29 fear response GO:0042596 9.51 ADRB1 DBH
30 adrenergic receptor signaling pathway GO:0071875 9.46 ADRA2A ADRA2B ADRA2C ADRB2
31 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
32 regulation of vasoconstriction GO:0019229 9.1 ADRA2A ADRA2B ADRA2C AGTR1 ECE1 EDN1
33 G-protein coupled receptor signaling pathway GO:0007186 10.1 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1

Molecular functions related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.99 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2 protein homodimerization activity GO:0042803 9.87 ACHE ADRA2A ADRA2C ADRB2 ECE1 NOS2
3 obsolete signal transducer activity GO:0004871 9.85 ADRA2A ADRA2B ADRB1 ADRB2 AGTR1
4 hormone activity GO:0005179 9.71 EDN1 FBN1 POMC
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.56 NOS2 NOS3
6 L-ascorbic acid binding GO:0031418 9.55 DBH PLOD1
7 FMN binding GO:0010181 9.52 NOS2 NOS3
8 arginine binding GO:0034618 9.49 NOS2 NOS3
9 NADPH-hemoprotein reductase activity GO:0003958 9.48 NOS2 NOS3
10 alpha-2A adrenergic receptor binding GO:0031694 9.43 ADRA2C ADRB1
11 norepinephrine binding GO:0051380 9.43 ADRA2A ADRB1 ADRB2
12 tetrahydrobiopterin binding GO:0034617 9.4 NOS2 NOS3
13 nitric-oxide synthase activity GO:0004517 9.37 NOS2 NOS3
14 adrenergic receptor activity GO:0004935 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
15 alpha2-adrenergic receptor activity GO:0004938 9.33 ADRA2A ADRA2B ADRA2C
16 epinephrine binding GO:0051379 9.02 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2

Sources for Orthostatic Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....